This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorMila Mend Inc.

About this trial

The rationale for this study is to observe the impact of a consumer-grade commercially available product called Milamend Hormone Balance on quality of life and hormonal health in women with self-reported symptoms associated with Polycystic Ovarian Syndrome (PCOS). Additionally, the study aims to observe the impact of the product on menstrual cycle structure and associated symptoms, on reproductive and metabolic markers, on body image concerns, anxiety and general well-being. A consumer-driven, decentralized observational clinical research study is therefore well-suited for examining the effects of this product in this population.

We will examine the outcomes in a broad age-range of premenopausal women who have chosen to try this product. The study will incorporate participant reported outcome questionnaires and surveys and at-home blood specimen collection. There is no "doctor-patient" relationship as part of this research since the participant as a consumer is making the informed choice to try the product and take part in the observational process with self-reported measures, cycle tracking and at-home blood sample collection. Findings from this study will contribute knowledge toward the tolerability and formulation of the product and the design of future studies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Females between 18-40 years old, inclusive

Oligomenorrhea (<9 menstrual cycles in the past year)

Signs of hyperandrogenism (hirsutism, acne, female-pattern hair loss)

Has recorded menstrual cycle duration of at least 3 menstrual cycles in the past year

Disqualifiers

Do not have a personal smartphone, internet access, or unwilling to download Chloe.

Rates the impact of PCOS on their overall quality of life as "Rarely/Seldom" or "Not at all"

Average cycle length of last 3 cycles is >50 days

Use of hormonal contraceptives within the last 6 months.

Trial design

Design model

Parallel

Treatments tested in this trial

  • A dietary supplement powder for women

    Dietary supplement

    1 scoop/day mixed with ≥8 oz water for the first 3 days at study start and then increase to 1 scoop twice daily (AM/PM) with food.

  • Placebo

    Dietary supplement

    1 scoop/day mixed with ≥8 oz water for the first 3 days at study start and then increase to 1 scoop twice daily (AM/PM) with food.

Treatment groups

225 Participants
are divided into 2 treatment groups
Group A: Placebo ArmPlacebo comparator 1 intervention
Group B: Study Product ArmExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Quality of Life Impact

To evaluate the impact of Milamend product on quality of life associated with PCOS symptoms. Change in health-related quality of life score between placebo and study product group as measured by the PCOS-QOL. Baseline will be compared as well.

Time frame
13 weeks

Secondary outcomes

1

Menstrual Cycle Frequency, Function and Length Impact

To evaluate the impact of Milamend on menstrual cycle frequency. Change in presence of LH surges between study product and placebo groups.

Time frame
12 weeks
2

Menstrual Cycle Symptoms Impact

To evaluate the impact of Milamend on menstrual cycle symptoms. Change in the incidence, characteristics and/or severity of cycle symptoms between study product and placebo groups.

Time frame
12 weeks
3

General Well-Being Impact

To evaluate the impact of Milamend product on general well-being. Change in general well-being score between placebo and study product group as measured by the Patient Health Questionnaire-9 (PHQ-9). Baseline will be compared as well.

Time frame
13 weeks
4

Impact on Anxiety

To evaluate the impact of Milamend on anxiety. Change in anxiety score between placebo and study product group as measured by GAD-7. Baseline will be compared as well.

Time frame
13 weeks

Other outcomes

1

Study Experience Assessment

To identify improvements for future participant-centered study designs using feedback Assessment of patient satisfaction survey of study experience including design and use of app-based data collection tools

Time frame
12 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mila Mend Inc.

Lead sponsor

People Science, Inc.

Collaborator